Inside Your Health: Ozempic and Zepbound
Video Player is loading.
Two major FDA approvals could change the way we treat sleep apnea and diabetes-related kidney disease.
On Tuesday, the agency gave the green light for Ozempic to help protect kidney function in people with diabetes and Zepbound as the first-ever drug treatment for sleep apnea in people with obesity.
Both of these GLP-1 drugs were originally designed for diabetes, but their benefits keep expanding — KSTP health expert Dr. Archelle Georgiou is here with more information.